Alligator Bioscience AB: Interim report January–March 2021
High activity during the first quarter ”So far, 2021 has been characterized by high activity, with a research collaboration that validates our Discovery concept, and good progress of our clinical programs, with ATOR-1017 and mitazalimab entering clinical efficacy studies this year.” Malin Carlsson, Interim CEO Alligator Bioscience ABSIGNIFICANT EVENTS JANUARY-MARCH Pipeline: · New preclinical data were released in an abstract for a poster presentation at the AACR Annual Meeting 2021, demonstrating that mitazalimab synergizes with chemotherapy. Company: · Søren